The KEAP1 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung adenocarcinoma epithelial cell line, featuring disruption of the endogenous KEAP1 gene. This genetically heterogeneous pool provides a robust in vitro system for interrogating KEAP1-dependent regulatory mechanisms without clonal selection bias, enabling studies of average population-level responses to genetic perturbation in a cancer-relevant background.
The A-549 host cell line was derived from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and is widely employed as an adherent epithelial model for non-small cell lung cancer. These cells retain characteristic molecular features of alveolar type II pneumocytes and are extensively utilized in oxidative stress research, drug resistance profiling, and investigations of redox homeostasis, making them an appropriate background for examining KEAP1 function in pulmonary carcinogenesis.
KEAP1 operates as a redox-sensitive substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, controlling the stability of transcription factor NRF2. In the absence of stress, KEAP1 binds the Neh2 domain of NRF2, facilitating its ubiquitination and constitutive proteasomal degradation. Exposure to reactive oxygen species, electrophiles, or the autophagy adaptor p62/SQSTM1 modifies key cysteine residues of KEAP1, disrupting complex assembly and allowing newly synthesized NRF2 to accumulate and translocate to the nucleus. There, NRF2 partners with small MAF proteins to activate antioxidant response element (ARE)-driven expression of detoxifying and antioxidant genes, such as NQO1, HMOX1, GCLC, GCLM, TXNRD1, and SLC7A11. This pathway also governs ferroptosis sensitivity through SLC7A11 and GPX4, and intersects with PI3K/AKT and PKC signaling upstream, as well as NRF2-mediated feedback regulation. Interacting partners including PGAM5 and IKK?? further expand the signal integration capacity of the KEAP1-NRF2 axis.
In A-549 lung adenocarcinoma cells, KEAP1 loss recapitulates a common oncogenic mechanism, as somatic mutations or silencing of KEAP1 occur in a substantial fraction of non-small cell lung cancers, driving constitutive NRF2 activation and promoting cell survival under oxidative stress and chemotherapeutic challenges. This knockout model therefore serves as a relevant platform for dissecting NRF2-mediated drug resistance, assessing metabolic reprogramming through the pentose phosphate pathway and glutathione synthesis, and evaluating susceptibility to ferroptosis induction. Use of polyclonal populations avoids confounding effects of single-clone adaptation and better mirrors tumor heterogeneity, strengthening translational relevance for targeted therapy development.
This polyclonal KEAP1 knockout pool enables diverse functional assays, including western blot detection of NRF2 and downstream targets, RT-qPCR profiling of antioxidant gene induction, ROS quantification, glutathione measurement, and viability assays under oxidative or chemotherapeutic stress. Ferroptosis studies employing lipid peroxidation sensors and GPX4 expression analysis are particularly relevant, while ARE-luciferase reporters, co-immunoprecipitation of NRF2 complexes, and immunofluorescence visualization of NRF2 nuclear localization provide mechanistic insights. The model is suited for screening KEAP1-NRF2 pathway modulators, investigating drug resistance in NSCLC, and exploring oxidative stress contributions to neurodegenerative or metabolic disease. For technical inquiries, contact Ascent Research.
